Kovitz Investment Group Partners LLC Buys New Stake in Hologic, Inc. (NASDAQ:HOLX)
Kovitz Investment Group Partners LLC bought a new stake in Hologic, Inc. (NASDAQ:HOLX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 20,250 shares of the medical equipment provider’s stock, valued at approximately $919,000.
A number of other large investors have also recently bought and sold shares of HOLX. TrimTabs Asset Management LLC raised its stake in shares of Hologic by 88.8% in the first quarter. TrimTabs Asset Management LLC now owns 2,993 shares of the medical equipment provider’s stock worth $127,000 after buying an additional 1,408 shares during the last quarter. Beck Mack & Oliver LLC bought a new stake in shares of Hologic during the second quarter worth approximately $209,000. Notis McConarty Edward bought a new stake in shares of Hologic during the second quarter worth approximately $213,000. Advisor Partners LLC bought a new stake in shares of Hologic during the first quarter worth approximately $201,000. Finally, CAPROCK Group Inc. bought a new stake in shares of Hologic during the second quarter worth approximately $214,000. Institutional investors own 94.46% of the company’s stock.
Shares of Hologic, Inc. (HOLX) opened at 38.33 on Thursday. The company has a market cap of $10.75 billion, a P/E ratio of 14.28 and a beta of 0.90. The company’s 50 day moving average is $44.21 and its 200 day moving average is $42.94. Hologic, Inc. has a one year low of $35.15 and a one year high of $46.80.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.01. The company had revenue of $806.10 million during the quarter, compared to analyst estimates of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.51 earnings per share. On average, equities analysts predict that Hologic, Inc. will post $2.01 earnings per share for the current year.
A number of brokerages recently commented on HOLX. Jefferies Group LLC restated a “buy” rating and set a $49.00 price objective on shares of Hologic in a report on Wednesday, June 28th. Barclays PLC reaffirmed an “overweight” rating and issued a $53.00 target price (up previously from $50.00) on shares of Hologic in a research report on Monday, July 17th. BidaskClub downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Stifel Nicolaus reaffirmed a “buy” rating on shares of Hologic in a research report on Friday, July 14th. Finally, Bank of America Corporation reaffirmed a “neutral” rating and issued a $48.00 target price (up previously from $44.00) on shares of Hologic in a research report on Friday, July 21st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $48.64.
In other Hologic news, Director Elaine Ullian sold 6,902 shares of the stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $40.12, for a total transaction of $276,908.24. Following the completion of the transaction, the director now owns 23,810 shares in the company, valued at $955,257.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lawrence M. Levy sold 9,193 shares of the stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $42.93, for a total transaction of $394,655.49. Following the transaction, the director now owns 46,206 shares of the company’s stock, valued at approximately $1,983,623.58. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 60,627 shares of company stock valued at $2,632,911. 0.79% of the stock is owned by company insiders.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.